BioLife Solutions (NASDAQ:BLFS) Price Target Cut to $27.00 by Analysts at HC Wainwright

BioLife Solutions (NASDAQ:BLFS - Get Free Report) had its price target dropped by HC Wainwright from $29.00 to $27.00 in a research report issued on Monday,Benzinga reports. The firm presently has a "buy" rating on the medical equipment provider's stock. HC Wainwright's price target points to a potential upside of 31.90% from the company's previous close.

Several other equities analysts have also weighed in on the stock. TD Cowen lifted their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Craig Hallum raised their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Finally, Northland Securities lifted their target price on BioLife Solutions from $26.00 to $28.00 and gave the company an "outperform" rating in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $27.50.

BioLife Solutions Trading Down 2.6 %

Shares of BLFS stock traded down $0.55 on Monday, reaching $20.47. 700,551 shares of the company's stock were exchanged, compared to its average volume of 381,227. The company's fifty day simple moving average is $24.00 and its 200 day simple moving average is $22.82. The company has a current ratio of 2.78, a quick ratio of 1.81 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $949.60 million, a PE ratio of -19.83 and a beta of 1.88. BioLife Solutions has a 52 week low of $11.91 and a 52 week high of $28.88.

Insider Buying and Selling at BioLife Solutions

In other news, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total transaction of $239,000.00. Following the completion of the transaction, the executive vice president now directly owns 317,716 shares in the company, valued at approximately $7,593,412.40. This represents a 3.05 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CRO Garrie Richardson sold 3,070 shares of the company's stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the sale, the executive now directly owns 114,773 shares in the company, valued at approximately $2,883,097.76. This represents a 2.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,471 shares of company stock valued at $656,330 over the last quarter. Corporate insiders own 2.20% of the company's stock.

Institutional Trading of BioLife Solutions

Hedge funds have recently added to or reduced their stakes in the business. Stifel Financial Corp boosted its position in shares of BioLife Solutions by 5.4% in the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider's stock valued at $325,000 after acquiring an additional 670 shares during the period. Louisiana State Employees Retirement System boosted its position in BioLife Solutions by 4.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider's stock worth $392,000 after acquiring an additional 700 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider's stock valued at $83,000 after acquiring an additional 748 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in BioLife Solutions by 5.8% during the second quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider's stock worth $296,000 after purchasing an additional 753 shares during the period. Finally, Sei Investments Co. grew its stake in BioLife Solutions by 1.4% in the 1st quarter. Sei Investments Co. now owns 60,191 shares of the medical equipment provider's stock valued at $1,117,000 after buying an additional 839 shares during the last quarter. Institutional investors own 93.24% of the company's stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.